{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(7)"],"submitter":["Luo Y"],"funding":["Sanofi"],"pubmed_abstract":["<h4>Introduction</h4>China has the world's largest diabetes epidemic and has been facing a serious shortage of primary care providers for chronic diseases including diabetes. To help primary care physicians follow guidelines and mitigate the workload in primary care communities in China, we developed a guideline-based decision tree. This study aimed to validate it at 3 months with real-world data.<h4>Methods</h4>The decision tree was developed based on the 2017 Chinese Type 2 Diabetes (T2DM) guideline and 2018 guideline for primary care. It was validated with the data from two registry studies: the NEW2D and ORBIT studies. Patients' data were divided into two groups: the compliance and non-compliance group, depending on whether the physician's prescription was consistent with the decision "],"journal":["Diabetes therapy : research, treatment and education of diabetes and related disorders"],"pagination":["1887-1899"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8266924"],"repository":["biostudies-literature"],"pubmed_title":["A Guideline-Based Decision Tree Achieves Better Glucose Control with Less Hypoglycemia at 3 Months in Chinese Diabetic Patients."],"pmcid":["PMC8266924"],"pubmed_authors":["Yin H","Cui N","Huang Y","Liao X","Zhang X","Ji L","Luo Y","Li A","Zhao T","Sun X","Wu H","Zhang P"],"additional_accession":[]},"is_claimable":false,"name":"A Guideline-Based Decision Tree Achieves Better Glucose Control with Less Hypoglycemia at 3 Months in Chinese Diabetic Patients.","description":"<h4>Introduction</h4>China has the world's largest diabetes epidemic and has been facing a serious shortage of primary care providers for chronic diseases including diabetes. To help primary care physicians follow guidelines and mitigate the workload in primary care communities in China, we developed a guideline-based decision tree. This study aimed to validate it at 3 months with real-world data.<h4>Methods</h4>The decision tree was developed based on the 2017 Chinese Type 2 Diabetes (T2DM) guideline and 2018 guideline for primary care. It was validated with the data from two registry studies: the NEW2D and ORBIT studies. Patients' data were divided into two groups: the compliance and non-compliance group, depending on whether the physician's prescription was consistent with the decision ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2026-05-08T07:47:37.952Z","creation":"2022-02-10T21:37:58.267Z"},"accession":"S-EPMC8266924","cross_references":{"pubmed":["34050897"],"doi":["10.1007/s13300-021-01075-1"]}}